Phase II trial of carboplatin in the management of malignant mesothelioma.
Thirty-one patients with advanced malignant mesothelioma, previously untreated or having received only one prior cytotoxic regimen, were treated in a prospective, single-arm phase II trial with carboplatin (NSC 241240) at a dose of 150 mg/m2 per day intravenously (IV) for 3 days (450 mg/m2/course). One complete remission and four partial remissions were achieved, yielding an overall objective response rate of 16% (95% confidence interval [CI], 5.4% to 34%). The median duration of remission was 8 months (range, 5 to 17). Nonhematological toxicity was mild (only 12% with World Health Organization [WHO] grade 3 vomiting); 16% suffered WHO grade 3 to 4 hematological toxicity, but there were no life-threatening episodes and no treatment-related deaths. Carboplatin has modest activity against malignant mesothelioma and, because of its low toxicity, has a role in the management of this disease.
Department of Clinical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
D
D
Raghavan
P
P
Gianoutsos
J
J
Bishop
J
J
Lee
I
I
Young
P
P
Corte
P
P
Bye
B
B
McCaughan
D000293:Adolescent; D000328:Adult; D000368:Aged; D016190:Carboplatin; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D007262:Infusions, Intravenous; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D013997:Time Factors
D009944:Organoplatinum Compounds; D016190:Carboplatin